drugset / Trial / NCT05311397
A Study of A166 in Patients With Advanced Solid Malignant Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
Timeline
- Start
- 2018-08-09
- Primary completion
- 2026-06-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 0.1 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 0.3 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 0.6 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 1.2 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 2.4 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 3.6 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 4.8 mg/kg | — |
| Subject | TRASTUZUMAB BOTIDOTIN | Unknown | 6 mg/kg | — |